Clinical Study
Appropriate Patient Selection in the Management of Common Bile Duct Stones: When Not to Do ERCP
Table 1
Clinical, biochemical, and ultrasound risk features for the presence of CBD stones.
| |||||||||||||||||||||||||||||||||||||||||||||
1High clinical risk: history of pancreatitis, jaundice, or cholangitis. 2High biochemical risk: raised ALT or ALP or bilirubin. 3High ultrasound risk: dilated CBD >7 mm or visualized CBD stone. |